This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Peter de Haan
Chief Scientific Officer & Co-Founder at Amarna Therapeutics


Peter has a biology background and has been active in R&D for thirty years. His academic career started as a Virologist at the Wageningen University in The Netherlands, where he obtained his PhD in 1991. In 1991 he joined Novartis Seeds where he held several research management positions in the field of plant biotechnology. He is a co-founder of Phytovation B.V., formerly active in biopharmaceuticals and vaccine production, and of its subsidiary Viruvation B.V., which was active in developing a therapeutic AIDS vaccine. Throughout his career de Haan has worked on applications of virus-associated technologies. He has a long-standing expertise in virology, molecular biology, immunology, cell biology and is highly experienced in molecular cloning activities, tissue culture of mammalian cells and production of (recombinant) virus particles in mammalian cell systems. Peter has an H-index of 35, wrote more than fifty peer reviewed scientific articles and is (co-) inventor of more than fourteen different awarded patents and patent applications.

Peter de Haan's Network

Agenda Sessions

  • Simian virus 40 (SV40) as Gene Delivery Vectors